Colourised scanning electron micrograph of SARS-CoV-2: Credit NIAID - Colourised scanning electron micrograph of a VERO E6 cell (purple) exhibiting elongated cell projections and signs of apoptosis, after infection with SARS-COV-2 virus particles (pink). Credit: NIAID on Flickr CC BY 2.0
Colourised scanning electron micrograph of SARS-CoV-2: Credit NIAID - Colourised scanning electron micrograph of a VERO E6 cell ( purple ) exhibiting elongated cell projections and signs of apoptosis, after infection with SARS-COV-2 virus particles ( pink ). Credit: NIAID on Flickr CC BY 2. How the immune systems of patients with antibody deficiency respond to SARS-CoV-2 infection and vaccination will be investigated as part of a new national study co-led by UCL researchers. Funded by UK Research and Innovation (UKRI), 'COVID infection in patients with Antibody Deficiency' (COVAD) is part of a portfolio of UK-wide studies examining the immune responses in patients considered at high risk of COVID-19. Immunodeficiency patients are considered vulnerable or extremely vulnerable to COVID-19 infection and have had to undertake preventative measures to minimise their risk of exposure to the virus. Patients with antibody deficiency do not make good responses - if any - to most vaccines, but it is not known whether they will respond to COVID-19 vaccines. The study is being led by the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, and UCL.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
